NR4A1 and breast carcinoma: We queried the National Cancer Database (NCDB) for practice patterns and survival outcomes in node-negative T1c-T2 female breast cancer patients with hormone receptor-positive/HER2-negative tumors and Oncotype DX Recurrence Score of 11–25, with a focus on the use of adjuvant chemotherapy.